x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAB-0012886
| Product Information | |
|---|---|
| Clonality | Monoclonal |
| Isotype | IgG |
| Host Species | Rabbit |
| Reactivity | Human, Mouse, Rat |
| Applications | WB |
| Product Description | Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding His900 of human TECPR1 protein. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | TECPR1 |
| UniProt No. | Q7Z6L1 |
| Gene ID | 25851 |
| Gene Description | Tectonin β-propeller repeat protein was first identified as DKFZP434B0335, a human ortholog of the yeast protein Pex23p. TECPR1 contains a pleckstrin homology domain, β-propeller domain, and dysferlin domains. Research studies have shown that elevated expression of TECPR1 may be a potential marker for prostate cancer. In several independent studies, TECPR1 was shown to play a role in autophagy through interaction with Atg5. Atg5 is a protein that is conjugated to the ubiquitin-like protein Atg12 and plays an essential role in autophagy. Initial studies suggested that TECPR1 plays a role in selective autophagy processes by targeting bacterial pathogens, as well as damaged mitochondria and protein aggregates. TECPR1 appears to be important for autophagosome maturation and promotes autophagosome fusion with the lysosome. Deletion of TECPR1 leads to an accumulation of autophagosomes. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
